Success Metrics

Clinical Success Rate

91.7%

Based on 166 completed trials

Completion Rate

92%(166/181)

Active Trials

16(7%)

Results Posted

78%(130 trials)

Terminated

15(7%)

Phase Distribution

Ph phase_3

13%

Ph phase_4

28%

Ph phase_1

Ph phase_2

28%

Ph early_phase_1

Ph not_applicable

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution213 total trials

Early Phase 1First-in-human

5(2.3%)

Phase 1Safety & dosage

16(7.5%)

Phase 2Efficacy & side effects

63(29.6%)

Phase 3Large-scale testing

29(13.6%)

Phase 4Post-market surveillance

62(29.1%)

N/ANon-phased studies

38(17.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.0%

166 of 193 finished

Non-Completion Rate

14.0%

27 ended early

Currently Active

trials recruiting

Total Trials

223

all time

Status Distribution

Active(18)

Completed(166)

Terminated(27)

Other(12)

Detailed Status

Completed166

Terminated15

Recruiting12

unknown12

Withdrawn12

Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials

223

Active

Success Rate

91.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 15 (2.3%)

Phase 116 (7.5%)

Phase 263 (29.6%)

Phase 329 (13.6%)

Phase 462 (29.1%)

N/A38 (17.8%)

Trials by Status

not_yet_recruiting10%

recruiting125%

active_not_recruiting42%

completed16674%

enrolling_by_invitation10%

unknown125%

withdrawn125%

terminated157%

Recent Activity

16 active trials

Showing 5 of 223

active_not_recruitingphase_2

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

NCT06006143

recruitingnot_applicable

Clinical Trials (223)

Showing 20 of 223 trialsScroll for more

NCT06006143Phase 2

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

Active Not Recruiting

NCT05642715Not Applicable

Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes

Recruiting

NCT06474299Phase 4

The Avenues Study: Dual Use Cessation

Recruiting

NCT06679374Phase 2

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Recruiting

NCT02271919Phase 4

Varenicline and Combined NRT for Smoking Cessation

Active Not Recruiting

NCT02162849Phase 4

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Active Not Recruiting

NCT04634071Phase 2

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Completed

NCT07145866Phase 4

Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)

Not Yet Recruiting

NCT06883162Phase 3

Cannabis-Tobacco Co-Use Treatment Study

Recruiting

NCT05694637Phase 4

Botswana Smoking and Abstinence Reinforcement Trial

Enrolling By Invitation

NCT03227679Not Applicable

Metabolism-informed Care for Smoking Cessation

Completed

NCT06854406Phase 1

A Study of Varenicline in the Treatment of Visceral Sensation

Completed

NCT04176172Phase 3

Optimizing Tobacco Use Treatment for PLWHA

Recruiting

NCT04590404Phase 3

Metabolism Informed Smoking Treatment: The MIST RCT

Completed

NCT01098955Early Phase 1

Smoking Cessation Treatment for Head & Neck Cancer Patients

Active Not Recruiting

NCT06218823Phase 4

Tobacco Treatment Comparison for Cancer Care

Completed

NCT04445662Not Applicable

Financial Incentives for Homeless Smokers: A Community-based RCT

Completed

NCT04604509Phase 4

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Recruiting

NCT03262662Phase 3

EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking

Completed

NCT04199117Phase 4

Health Systems Reach Interventions Project

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 223